Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Krishnan R. Patel, Eli Rosenbaum, Marla Johnson, Hyunnam Monica Ryu, James A. Proudfoot, Elai Davicioni, Daniel Eidelberg Spratt, Howard M. Sandler, Mack Roach, Seth A. Rosenthal, Adam P. Dicker, Nirav S. Kapadia, Rohann Correa, Fan Zhu, Samir Patel, Comron Hassanzadeh, Jason A. Efstathiou, Stephanie L. Pugh, Paul Nguyen, Phuoc T. Tran
Institutions: National Institutes of Health, National Cancer Institute, Rabin Medical Center, Veracyte (United States), University Hospitals Seidman Cancer Center, Case Western Reserve University, Oregon Health & Science University, University of California, San Francisco, Sutter Health, Sutter Medical Center, Thomas Jefferson University, Dartmouth Health, Dartmouth Cancer Center, Western University, Lawson Health Research Institute, Medical College of Wisconsin, Cross Cancer Institute, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, NRG Oncology, Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162508250